Clinical Trial Search

Primary: Percentage of Patients Alive and Free of Progression at 6 Months — 27 percentage of patients

Primary: Number of Participants Who Experience a Pathologic Complete Response (pCR) — 0; 0 Participants

Primary: Mean Percent Change in p16 Methylation (% CpG Sites Methylated) in Tumor Tissue After Soy Isoflavone — 4.9 Percent change — p=<0.005

Primary: Assess the Safety of the Study Drug by Calculating the Proportion of Patients Who Experience Grade 4 or 5 Study Drug Related Adverse Events, as Assessed by CTCAE v 4.03…

Primary: Overall Survival: Time From Randomization to Death From Any Cause — 74.9; 72.8 percentage of participants — p=0.68

Primary: Overall Survival (OS) — 8.4; 11.3 Months — p=0.9963

Primary: Overall Progression-Free Survival (PFS). — 370 Days

Primary: Change in Immune-based Biomarker Expression at Baseline and 2 Months — 0; 1; 2 Participants — p=<0.036

Primary: Percent (%) Change in Levels of pS6, pAKt473, and Ki-67 — -60.60; -67.24; -31.48; 100.00 percentage of change from baseline

Primary: Overall Response Rate at 4 Months — 16 percentage of participants

Primary: Oropharyngeal Leak Pressure — 25.06; 28.24; 22.88; 26.62 cm H20

Primary: Two Years Overall Survival (OS) — 24.7; 13.4 percentage of participants

Primary: Number of Participants With Cormack-Lehane Grade >2 Obtained With CMAC D Blade — 37 Participants

Primary: Progression-free Survival (PFS) Time: Independent Read Assessments — 1.5; 1.9 months — p=0.793

Primary: Detection of Malignancy in Excised Lymph Nodes by Pathology or Labeling With Lymphoseek and/or Panitumumab-IRDye800 — 10; 5; 3; NA Lymph nodes